B型肝炎ウイルス(HPV)治療市場:アメリカの治療薬市場

◆英語タイトル:Hepatitis B Virus (HBV) Therapeutics - US Drug Forecast and Market Analysis to 2024
◆商品コード:GDHC281CFR
◆発行会社(調査会社):GlobalData
◆発行日:2016年1月15日
◆ページ数:209
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD4,995 ⇒換算¥569,430見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD9,990 ⇒換算¥1,138,860見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD14,985 ⇒換算¥1,708,290見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

Hepatitis B Virus (HBV) Therapeutics – US Drug Forecast and Market Analysis to 2024
Summary

Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains a serious global health concern, with estimated over 350 million people worldwide currently living with this condition. In addition, patients with chronic hepatitis B are at a high risk of developing life-threatening complications including liver cirrhosis and hepatocellular carcinoma (HCC). In 2010, an estimated 786,000 HBV-related deaths occurred worldwide.

Available treatment for chronic hepatitis B focuses on viral suppression, and include oral nucleos(t)ide analogues (NAs) and pegylated interferon (PEG-IFN). The two therapy classes have distinctive strengths and weaknesses. Nevertheless, most patients are using long-term NA treatment, and suffer from issues such as high accumulated treatment cost and low compliance.

The US chronic hepatitis B therapeutics market was valued at $772.8m in 2014. The main driver of the US market over the forecast period will be the launch of novel therapies: most notably, the three adjunct therapies. These agents are aimed to be used alongside marketed oral NAs, and to improve the immunological cure rate, which is measured by the clearance or seroconversion of HBsAg and sustained HBV DNA suppression.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

- Overview of HBV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting the US HBV market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HBV.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2014-2024 in US.

【レポートの目次】

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Overview
3.2 Etiology and Pathophysiology
3.2.1 Etiology
3.2.2 Pathophysiology
3.3 Symptoms
3.4 Prognosis
3.4.1 Phases of Chronic HBV Infection
3.4.2 Complications of Chronic Hepatitis B
3.5 Quality of Life
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Diagnosis
4.1.2 Treatment Guidelines and Leading Prescribed Drugs
4.1.3 Clinical Practice
4.2 US
4.2.1 Screening and Diagnosis
4.2.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Product Profiles – Major Brands
5.2.1 Baraclude (entecavir)
5.2.2 Viread (tenofovir disoproxil fumarate)
5.2.3 Pegasys (peginterferon alfa-2a)
5.2.4 Hepsera (adefovir dipivoxil)
5.2.5 Tyzeka (telbivudine)
5.3 Other Therapeutics
5.3.1 Conventional and Pegylated Interferon alfa
5.3.2 Nucleos(t)ide Analogs
6 Unmet Need and Opportunity
6.1 Overview
6.2 Improvements in Long-Term Clinical Outcomes
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Enhanced Public Awareness and Screening Initiatives to Boost Diagnosis Rates
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Increased Access to Treatment
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Drugs That Effectively Target and Suppress HBV cccDNA
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
6.6 Safe and Efficacious Therapies for Difficult-to-Treat Patients
6.6.1 Unmet Need
6.6.2 Gap Analysis
6.6.3 Opportunity
6.7 Overcome Unique Barriers Posed by China’s Healthcare System
6.7.1 Unmet Need
6.7.2 Gap Analysis
6.7.3 Opportunity
7 Pipeline Assessment
7.1 Overview
7.2 Clinical Trial Mapping
7.2.1 Clinical Trials by Phase and Status, Therapy Class, and Location
7.3 Promising Drugs in Clinical Development
7.3.1 Tenofovir Alafenamide Fumarate
7.3.2 ARC-520
7.3.3 GS-9620
7.3.4 GS-4774
7.4 Other Drugs in Development
7.4.1 ABX-203
7.4.2 REP 2139-Ca
7.4.3 Besifovir
7.4.4 Hepabulin
7.4.5 Myrcludex-B
7.4.6 Agents in Early Stages of Development
8 Market Outlook
8.1 US
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Total Prevalent Cases of Chronic Hepatitis B
9.4.2 Diagnosed Chronic Hepatitis B Patients
9.4.3 Percent Drug-Treated Chronic Hepatitis B Patients
9.4.4 Drugs Included in Each Therapeutic Class
9.4.5 Launch and Patent Expiry Dates
9.4.6 General Pricing Assumptions
9.4.7 Individual Drug Assumptions
9.4.8 Generic Erosion
9.4.9 Pricing of Pipeline Agents
9.5 Primary Research – KOLs Interviewed for this Report
9.6 Primary Research – Prescriber Survey
9.7 About the Authors
9.7.1 Analyst
9.7.2 Therapy Area Director
9.7.3 Epidemiologists
9.7.4 Global Director of Therapy Analysis and Epidemiology
9.7.5 Global Head of Healthcare
9.8 About GlobalData
9.9 Disclaimer

1.1 List of Tables
Table 1: Modes of HBV Transmission
Table 2: HBV Serological Markers and Test Interpretations
Table 3: Symptoms of HBV Infection
Table 4: Phases of Chronic Hepatitis B Infection
Table 5: Key Complications of Chronic HBV infection
Table 6: Treatment Guidelines for Chronic Hepatitis B
Table 7: Most Prescribed Drugs for Chronic Hepatitis B by Class in the 8MM, 2014
Table 8: Country Profile - US
Table 9: Leading Treatments for Chronic Hepatitis B, 2015
Table 10: Product Profile - Baraclude
Table 11: Antiviral Efficacy of Baraclude Compared with Epivir-HBV
Table 12: Antiviral Efficacy of Baraclude in Epivir-HBV-Refractory Patients
Table 13: Baraclude SWOT Analysis, 2015
Table 14: Global Sales Forecasts ($m) for Baraclude, 2014-2024
Table 15: Product Profile - Viread
Table 16: Antiviral Efficacy of Viread Compared with Hepsera
Table 17: Viread SWOT Analysis, 2015
Table 18: Global Sales Forecasts ($m) for Viread, 2014-2024
Table 19: Product Profile - Pegasys
Table 20: Antiviral Efficacy of Pegasys Monotherapy Compared with Epivir-HBV Monotherapy or the Combination of the Two
Table 21: Pegasys SWOT Analysis, 2015
Table 22: Global Sales Forecasts ($m) for Pegasys, 2014-2024
Table 23: Product Profile - Hepsera
Table 24: Antiviral Efficacy of Hepsera in HBeAg-positive patients
Table 25: Long-term Antiviral Efficacy of Hepsera in HBeAg-negative patients
Table 26: Hepsera SWOT Analysis, 2015
Table 27: Global Sales Forecasts ($m) for Hepsera, 2014-2024
Table 28: Product Profile - Tyzeka
Table 29: Antiviral Efficacy of Tyzeka Compared with Epivir-HBV
Table 30: Tyzeka SWOT Analysis, 2015
Table 31: Global Sales Forecasts ($m) for Tyzeka, 2014-2024
Table 32: Summary of Minor Therapeutics for Chronic HBV Infection, 2015
Table 33: Unmet Needs and Opportunities in Chronic HBV Infection
Table 34: HBV - Clinical Trials by Phase and Status, 2015
Table 35: Key Late-Stage Pipeline Agents for Chronic Hepatitis B Treatment, 2015
Table 36: Product Profile - TAF
Table 37: TAF SWOT Analysis, 2015
Table 38: Global Sales Forecasts ($m) for TAF, 2014-2024
Table 39: Product Profile - ARC-520
Table 40: Safety of ARC-520 from a Phase I Clinical Trial
Table 41: ARC-520 SWOT Analysis, 2015
Table 42: Global Sales Forecasts ($m) for ARC-520, 2014-2024
Table 43: Product Profile - GS-9620
Table 44: GS-9620 SWOT Analysis, 2015
Table 45: Global Sales Forecasts ($m) for GS-9620, 2014-2024
Table 46: Product Profile - GS-4774
Table 47: Phase I Clinical Trial Efficacy Results of GS-4774 in Healthy Participants
Table 48: Phase I Clinical Trial Safety Results of GS-4774 in Healthy Participants
Table 49: GS-4774 SWOT Analysis, 2015
Table 50: Global Sales Forecasts ($m) for GS-4774, 2014-2024
Table 51: Other Agents in Clinical Development for Chronic Hepatitis B Treatment, 2015
Table 52: Agents in Phase I or early Phase II Clinical Development for Chronic Hepatitis B Treatment, 2015
Table 53: Agents in Preclinical Development for Chronic Hepatitis B Treatment, 2015
Table 54: Sales Forecasts ($m) for Chronic Hepatitis B Therapeutics in the US, 2014-2024
Table 55: Key Events Impacting Sales for Chronic Hepatitis B Therapeutics in the US, 2014-2024
Table 56: Chronic Hepatitis B Therapeutics Market - Drivers and Barriers in the US, 2014-2024
Table 57: Key Historical and Projected Launch Dates
Table 58: Key Historical and Projected Patent Expiry Dates
Table 59: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country

1.2 List of Figures
Figure 1: Key Steps in HBV Replication and Potential Therapeutic Targets
Figure 2: HBV Structure
Figure 3: Prognosis of Chronic HBV infection
Figure 4: Treatment Algorithm for Chronic HBV Infection in Non-cirrhotic, HBeAg-Positive Patients
Figure 5: Treatment Algorithm for Chronic HBV Infection in Non-cirrhotic, HBeAg-Negative Patients
Figure 6: Chronic hepatitis B Therapeutics - Therapy Class and Trial Location, 2014
Figure 7: HBV Phase II/Phase III Pipeline, 2014
Figure 8: Competitive Assessment of Late-Stage Pipeline Agents for Chronic Hepatitis B, 2015
Figure 9: Clinical and Commercial Positioning of TAF
Figure 10: Clinical and Commercial Positioning of ARC-520
Figure 11: Clinical and Commercial Positioning of GS-9620
Figure 12: Clinical and Commercial Positioning of GS-4774
Figure 13: Sales for Chronic Hepatitis B Therapeutics in the US by Therapy Class, 2014-2024

★調査レポート[B型肝炎ウイルス(HPV)治療市場:アメリカの治療薬市場]販売に関する免責事項
★調査レポート[B型肝炎ウイルス(HPV)治療市場:アメリカの治療薬市場]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆